Abiopharma

Update regurding compliance with Nasdaq Listing Rule

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Regency Centers Declares Quarterly Dividends

Ocean Power Technologies Advances Offshore Charging and Autonomous Operations for Maritime Drones

Starstream Entertainment Inc. Completes Name Change to CityWalk e-Bike Inc: A Company Focused on Electric & Hydrogen e-Bike Rental & Manufacturing in China: Begins Trading Under New Symbol OTCID: CWLK

Inuvo to Host First Quarter 2026 Financial Results Conference Call on Thursday, May 14th at 4:15 P.M. ET

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2026

Net Asset Value(s)